REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat
Regeneron (REGN) raised its full-year R&D spending forecast to $6.60B-$6.74B and capital expenditure guidance to $1.05B-$1.10B. The company's CFO stated it is positioned for one of its strongest years ever after Q3 earnings beat. REGN shares are up nearly 15% in 2026, with bullish retail sentiment on Stocktwits.
How this was made
The 30-second read
Why it matters
Guidance raise may boost Regeneron's stock and lift biotech sentiment.
Market read
Regeneron's guidance upgrade is likely to influence biotech sector sentiment and investor positioning.
What to watch
Potential regulatory risks for new R&D projects could temper upside.
Background
Regeneron reported a Q3 earnings beat and the CFO provided updated FY guidance.
Ticker impact
Regeneron raised its FY R&D spending forecast to $6.60‑$6.74 billion and capex guidance to $1.05‑$1.10 billion.
upward pressure as investors price in stronger guidance and earnings beat.
The increased R&D and capex outlook signals a robust pipeline, supporting a higher valuation.
Market effects
Biotech sector may benefit from Regeneron's stronger pipeline and higher spending guidance.
US biotech stocks could see uplift following the guidance raise.
International investors may adjust exposure to biotech based on Regeneron's outlook.
Counterpoint
Higher capex could strain cash flow if sales do not keep pace with spending.
Key entities
- companyRegeneron Pharmaceuticals
US biotech firm that issued the guidance update.
- executiveCFO (unnamed)
Provided the new R&D and capex forecasts.
